Literature DB >> 1504110

Anxiogenic properties of yohimbine. I. Behavioral, physiological and biochemical measures.

M Albus1, T P Zahn, A Breier.   

Abstract

The anxiogenic effects of yohimbine, a specific alpha-2-receptor antagonist were examined by administering 20 mg yohimbine orally to 8 panic patients on placebo treatment, 7 panic patients on alprazolam treatment and 12 controls using a double-blind randomized design, instructions that minimized the expectancy of experiencing a panic attack and two additional structured situations. Yohimbine induced more pronounced increases in anxiety and panicky ratings, norepinephrine secretion, maximum heart rate and high heart rate variability and decreases in skin temperature in panic patients compared with controls. However, possibly owing to an instructional set and experimental design that distracted patients from unpleasant bodily sensations no panic attacks were observed.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1504110     DOI: 10.1007/bf02191958

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  44 in total

1.  Yohimbine as an autonomic test drug.

Authors:  G HOLMBERG; S GERSHON; L H BECK
Journal:  Nature       Date:  1962-03-31       Impact factor: 49.962

2.  Ventilatory physiology of patients with panic disorder.

Authors:  J M Gorman; M R Fyer; R Goetz; J Askanazi; M R Liebowitz; A J Fyer; J Kinney; D F Klein
Journal:  Arch Gen Psychiatry       Date:  1988-01

3.  Electroencephalographic sleep in panic disorder. A focus on sleep-related panic attacks.

Authors:  T A Mellman; T W Uhde
Journal:  Arch Gen Psychiatry       Date:  1989-02

4.  Behavioral, biochemical, and blood pressure responses to alprazolam in healthy subjects: interactions with yohimbine.

Authors:  D S Charney; A Breier; P I Jatlow; G R Heninger
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

5.  Serotonin function in anxiety. II. Effects of the serotonin agonist MCPP in panic disorder patients and healthy subjects.

Authors:  D S Charney; S W Woods; W K Goodman; G R Heninger
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

Review 6.  Increased anxiogenic effects of caffeine in panic disorders.

Authors:  D S Charney; G R Heninger; P I Jatlow
Journal:  Arch Gen Psychiatry       Date:  1985-03

7.  A comparison of lactate and isoproterenol anxiety states.

Authors:  J M Rainey; R B Pohl; M Williams; E Knitter; R R Freedman; E Ettedgui
Journal:  Psychopathology       Date:  1984       Impact factor: 1.944

8.  Sleep panic attacks: new clinical findings and theoretical implications.

Authors:  T A Mellman; T W Uhde
Journal:  Am J Psychiatry       Date:  1989-09       Impact factor: 18.112

9.  Liquid chromatographic assay for CSF catecholamines using electrochemical detection.

Authors:  T Seppala; M Scheinin; A Capone; M Linnoila
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1984-08

10.  Measurement of lactate-induced panic and anxiety.

Authors:  D J Dillon; J M Gorman; M R Liebowitz; A J Fyer; D F Klein
Journal:  Psychiatry Res       Date:  1987-02       Impact factor: 3.222

View more
  13 in total

Review 1.  Modeling relapse in animals.

Authors:  Rémi Martin-Fardon; Friedbert Weiss
Journal:  Curr Top Behav Neurosci       Date:  2013

2.  Yohimbine increases opioid-seeking behavior in heroin-dependent, buprenorphine-maintained individuals.

Authors:  Mark K Greenwald; Leslie H Lundahl; Caren L Steinmiller
Journal:  Psychopharmacology (Berl)       Date:  2012-11-17       Impact factor: 4.530

3.  Adrenergic transmission facilitates extinction of conditional fear in mice.

Authors:  Christopher K Cain; Ashley M Blouin; Mark Barad
Journal:  Learn Mem       Date:  2004 Mar-Apr       Impact factor: 2.460

Review 4.  Exploring exercise as an avenue for the treatment of anxiety disorders.

Authors:  Lindsey B DeBoer; Mark B Powers; Angela C Utschig; Michael W Otto; Jasper A J Smits
Journal:  Expert Rev Neurother       Date:  2012-08       Impact factor: 4.618

5.  The profiles of interaction of yohimbine with anxiolytic and putative anxiolytic agents to modify 5-HT release in the frontal cortex of freely-moving rats.

Authors:  C H Cheng; B Costall; J Ge; R J Naylor
Journal:  Br J Pharmacol       Date:  1993-11       Impact factor: 8.739

6.  Psychophysiological and biochemical changes in patients with panic attacks in a defined situational arousal.

Authors:  S Braune; M Albus; M Fröhler; T Höhn; G Scheibe
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1994       Impact factor: 5.270

7.  Yohimbine premedication and 35% CO2 vulnerability in healthy volunteers.

Authors:  H Pols; E Griez; K Verburg; D van der Werf
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1994       Impact factor: 5.270

8.  Modelling anxiety in humans for drug development.

Authors:  Martin Siepmann; Peter Joraschky
Journal:  Curr Neuropharmacol       Date:  2007-03       Impact factor: 7.363

9.  Anxiogenic properties of yohimbine. II. Influence of experimental set and setting.

Authors:  M Albus; T P Zahn; A Breier
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1992       Impact factor: 5.270

10.  Anxiolytic-like effects of yohimbine in the murine plus-maze: strain independence and evidence against alpha 2-adrenoceptor mediation.

Authors:  J C Cole; G J Burroughs; C R Laverty; N C Sheriff; E A Sparham; R J Rodgers
Journal:  Psychopharmacology (Berl)       Date:  1995-04       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.